3月17日,阿斯利康宣布III期CALYPSO研究取得积极结果,该研究旨在评估 eneboparatide(AZP-3601)在成人慢性甲状旁腺功能减退症(HypoPT)患者中的疗效和安全性。Eeneboparatide是2024年3月阿斯利康以10.5亿美元收购Amolyt Pharm获得的一款甲状旁腺激素(PTH)受体1激动剂。CALYPSO研究成为该药首个达到主要终点的III期临床研究,验证...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.